1 published article · Updated continuously
35 trials tracked for Carcinoma: 9 in phase 3 or 4 and 3 with published results. The most-cited published study has 973 citations.
Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Brigatinib demonstrated significant improvements in progression-free survival (PFS) and objective response rates (ORR), including a significantly higher intracranial ORR (iORR) compared to other cohorts (p<0.0001; p=0.0330) 5. Sorafenib showed statistically significant improvements in progression-free survival (p<0.0001) and disease control (p<0.000001), though it did not show a statistically significant difference in overall survival (p=0.4687) 8.
Aflibercept was associated with a statistically significant improvement in progression-free survival (PFS) (p=0.0035), while no significant difference was found in overall survival (OS) (p=0.8985) 9. Everolimus showed established disease control rates and specific timeframes for deterioration of ECOG Performance Scores and EORTC QLQ-C30 scores 6.
In studies involving 5-fluorouracil, the time to diagnosis of first keratinocyte carcinoma (KC) on the face or ears and the hazard ratio for surgically treated KC did not show statistically significant differences between groups (p=0.93) 1. Nab-paclitaxel was associated with high rates of peripheral neuropathy or myelosuppression (approximately 76-77%) and frequent dose reductions (57-65%) 4.
Other established interventions included Lorlatinib, which showed a confirmed intracranial objective response rate of 46.7% 2, and Everolimus in a separate study showing varying overall response rates at 12 months 16.
AI synthesis of 13 cited trials, updated Jul 9, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
